Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
6 evidence topics · 9 sources
FORTIFI-HN01 pivotal regimen
| Arm | Regimen |
|---|---|
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 optimal biological dose arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |
| Phase 3 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |
Doses studied in the phase 1b first-line HNSCC expansion cohorts
| Cohort | Ficerafusp alfa | Pembrolizumab |
|---|---|---|
| 750 mg weekly | “Ficerafusp alfa 750 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 1500 mg weekly | “Ficerafusp alfa 1500 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 2000 mg every 2 weeks | “Ficerafusp alfa 2000 mg Q2W” | “Pembrolizumab 400 mg Q6W” |
Doses studied in the phase 1 dose escalation
“At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MTD was not reached in either cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote